{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:26:22Z","timestamp":1791123982953,"version":"4.1.0"},"reference-count":95,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (UC); therefore, further information is needed, particularly regarding efficacy and safety. Objectives: To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. Methods: The PubMed and Scopus databases were considered, searching for \u2018JAK\u2019, \u2018JAK-inhibitor\u2019, \u2018Janus Kinases\u2019, \u2018Tofacitinib\u2019, \u2018Filgotinib\u2019, \u2018Upadacitinib\u2019, individually or in combination with \u2018IBD\u2019, \u2018Ulcerative Colitis\u2019, \u2018safety\u2019, \u2018efficacy\u2019, \u2018study\u2019 and \u2018trial\u2019. The search was focused on full-text papers published in English, with no publication date restrictions. Results: The efficacy and safety of JAK-i approved for treating patients with UC have been summarized. These included Tofacitinib, Filgotinib and Upadacitinib. Findings from both clinical trials and real-life studies in UC were reported, with particular regard to their efficacy in inducing clinical response and remission, steroid-free remission and endoscopic and histological healing. Overall, JAK-i proved to be effective and safe in selected subgroups of patients with UC. The rapid onset of action and the oral route of administration represent the most relevant characteristics of these drugs. Safety concerns using Tofacitinib in subgroups of patients (infections, hypercholesterolemia, venous thromboembolism and cardiovascular events) were initially raised. More recently, all JAK-i for UC showed an overall satisfactory safety profile. However, indication should be carefully given. Conclusions: The use of JAK-i UC is promising, although no predictive markers of response are currently available. Optimizing their use, as monotherapy or combined with other immunomodulators, may increase their efficacy in appropriately selected subgroups of patients with UC.<\/jats:p>","DOI":"10.3390\/jcm13237186","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T08:17:42Z","timestamp":1732695462000},"page":"7186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-7903","authenticated-orcid":false,"given":"Benedetto","family":"Neri","sequence":"first","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Mancone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariasofia","family":"Fiorillo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Concetta","family":"Schiavone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Migliozzi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9056-1957","authenticated-orcid":false,"given":"Livia","family":"Biancone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Department of Systems Medicine, University \u201cTor Vergata\u201d of Rome, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: The forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/MIB.0000000000000745","article-title":"Incidence of Crohn\u2019s disease and ulcerative colitis in Rhode Island: Report from the Ocean State Crohn\u2019s and Colitis Area Registry","volume":"22","author":"Shapiro","year":"2016","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and Pathogenesis of Ulcerative Colitis","volume":"49","author":"Du","year":"2020","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ecco-jcc\/jjz202","article-title":"Efficacy of JAK inhibitors in Ulcerative Colitis","volume":"14","author":"Ferrante","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/1751-2980.12937","article-title":"Histological scores in inflammatory bowel disease","volume":"22","author":"Neri","year":"2021","journal-title":"J. Dig. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: Histological remission in inflammatory bowel disease. Is \u2018complete\u2019 remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ibd\/izad119","article-title":"Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis","volume":"30","author":"Shehab","year":"2024","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.dld.2023.11.022","article-title":"Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study","volume":"56","author":"Vieujean","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomized controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14728214.2023.2254686","article-title":"Emerging oral drug options for ulcerative colitis","volume":"28","author":"Salvatori","year":"2023","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14656566.2024.2339926","article-title":"Comprehensive overview of novel chemical drugs for ulcerative colitis: Focusing on phase 3 and beyond","volume":"25","author":"Neri","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_28","unstructured":"US Food and Drug Administration, and Drug Safety Communications (2024, November 01). Safety Trial Finds Risk of Blood Clots in the Lungs and Death with Higher Dose of Tofacitinib (Xeljanz, Xeljanz XR) in Rheumatoid Arthritis Patients; FDA to Investigate, Available online: https:\/\/www.fda.gov\/media\/120485\/download."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dhaliwal, G., Patrone, M.V., and Bickston, S.J. (2023). Venous Thromboembolism in Patients with Inflammatory Bowel Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010251"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/ibd\/izaa199","article-title":"Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancy (excluding nonmelanoma skin cancer) events across the ulcerative colitis clinical program","volume":"27","author":"Lichtenstein","year":"2021","journal-title":"Inflam. Bowel. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/ibd\/izab056","article-title":"Tofacitinib for the treatment of ulcerative colitis: Analysis of nonmelanoma skin cancer rates from the ulcerative colitis clinical program","volume":"28","author":"Sands","year":"2022","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ueg2.12584","article-title":"Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure","volume":"12","author":"Sands","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ecco-jcc\/jjac187","article-title":"ECCO Guidelines on Inflammatory Bowel Disease and Malignancies","volume":"17","author":"Gordon","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-020-01346-4","article-title":"Safety of New Biologics (Vedolizumab and Ustekinumab) and Small Molecules (Tofacitinib) During Pregnancy: A Review","volume":"80","author":"Gisbert","year":"2020","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American gastroenterological association IBD parenthood project working group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.dld.2023.08.054","article-title":"New drugs for the treatment of IBD during conception, pregnancy, and lactation","volume":"56","author":"Pugliese","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_41","unstructured":"(2024, November 01). Xeljanz: EPAR n.d. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xeljanz-epar-product-information_en.pdf."},{"key":"ref_42","unstructured":"(2024, November 01). Rinvoq: EPAR n.d. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rinvoq-epar-product-information_en.pdf."},{"key":"ref_43","unstructured":"(2024, November 01). Jyseleca: EPAR n.d. Available online: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10067-021-06003-z","article-title":"Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: A systematic review and network meta-analysis","volume":"41","author":"Li","year":"2022","journal-title":"Clin. Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/1744666X.2023.2149495","article-title":"Filgotinib in rheumatoid arthritis","volume":"19","author":"Westhovens","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10067-023-06529-4","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: A systematic review and meta-analysis","volume":"42","author":"Yang","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): Results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Baraliakos","year":"2018","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ecco-jcc\/jjad039","article-title":"Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b\/3 SELECTION Trial","volume":"17","author":"Dotan","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: Update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_53","first-page":"1110","article-title":"Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years","volume":"83","author":"Burmester","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: A randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: A meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: Results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2147\/PPA.S417677","article-title":"Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives","volume":"17","author":"Tanaka","year":"2023","journal-title":"Patient Prefer. Adherence"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a randomized trial of patients with active Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: Results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e35689","DOI":"10.1097\/MD.0000000000035689","article-title":"Comparative of the effectiveness and safety of biological agents, small molecule drugs, and microbiome therapies in ulcerative colitis: Systematic review and network meta-analysis","volume":"102","author":"Gao","year":"2023","journal-title":"Medicine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases","volume":"83","author":"Quera","year":"2023","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e003392","DOI":"10.1136\/rmdopen-2023-003392","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Choy","year":"2023","journal-title":"RMD Open"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e002735","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12664-023-01434-9","article-title":"Upfront tofacitinib in patients with biological-na\u00efve ulcerative colitis\u2014An Indian multicentric experience","volume":"43","author":"Giri","year":"2024","journal-title":"Indian J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.dld.2023.08.061","article-title":"Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study","volume":"56","author":"Macaluso","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.3748\/wjg.v30.i13.1871","article-title":"Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis","volume":"30","author":"Kojima","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/ibd\/izad135","article-title":"Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study","volume":"30","author":"Bacsur","year":"2024","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1080\/14656566.2023.2230126","article-title":"Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: Data from a real-world study","volume":"24","author":"Tursi","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gros, B., Goodall, M., Plevris, N., Constantine-Cooke, N., Elford, A.T., O\u2019Hare, C., Noble, C., Jones, G.R., Arnott, I.D., and Lees, C.W. (2023). Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis. J. Crohns Colitis, jjad187. epub ahead of print.","DOI":"10.1093\/ecco-jcc\/jjad187"},{"key":"ref_72","first-page":"e61496","article-title":"Real-World Data on the Effectiveness and Safety of Filgotinib for Ulcerative Colitis in Japanese Patients: A Single-Center Experience","volume":"16","author":"Toba","year":"2024","journal-title":"Cureus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn\u2019s Disease: Prospective Real-World Experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/ibd\/izad155","article-title":"Clinical and Endoscopic Outcomes After Upadacitinib Induction for Ulcerative Colitis: A Multicenter Retrospective Cohort Study","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1093\/ibd\/izad279","article-title":"Use of Upadacitinib in 16 Tofacitinib-refractory Ulcerative Colitis Patients: A Single-center Case 2 Series","volume":"30","author":"Levine","year":"2024","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.2169\/internalmedicine.2653-23","article-title":"Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series","volume":"63","author":"Hosomi","year":"2024","journal-title":"Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2023.08.021","article-title":"Comparative Effectiveness of Upadacitinib vs Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study","volume":"22","author":"Dalal","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Kochhar, G.S., Khataniar, H., Jairath, V., Farraye, F.A., and Desai, A. (2024). Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study. Am. J. Gastroenterol., epub ahead of print.","DOI":"10.14309\/ajg.0000000000002947"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.14309\/ajg.0000000000002746","article-title":"Year Comparative Effectiveness of Upadacitinib vs Tofacitinib for Ulcerative Colitis: A Multicenter Cohort Study","volume":"119","author":"Dalal","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"i156","DOI":"10.1093\/ecco-jcc\/jjad212.0086","article-title":"Canadian IBD Research Consortium, DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis\u2014The TRIUMPH study","volume":"18","author":"Narula","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/ibd\/izad180","article-title":"Upadacitinib for acute severe ulcerative colitis","volume":"29","author":"Zinger","year":"2023","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/ecco-jcc\/jjad115","article-title":"Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis","volume":"17","author":"Gilmore","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10620-024-08302-2","article-title":"Upadacitinib as Rescue Therapy for the Treatment of Acute Severe Colitis in an Acute Care Setting","volume":"69","author":"Clinton","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"otad009","DOI":"10.1093\/crocol\/otad009","article-title":"Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis","volume":"5","author":"Panaccione","year":"2023","journal-title":"Crohns Colitis 360"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ananthakrishnan, A.N., Murad, M.H., Scott, F.I., Agrawal, M., Haydek, J.P., Limketkai, B.N., Loftus, E.V., and Singh, S. (2024). Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology, online ahead of print.","DOI":"10.1053\/j.gastro.2024.07.046"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/apt.18294","article-title":"Review article: Novel therapies in inflammatory bowel disease\u2014An update for clinicians","volume":"60","author":"Noor","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1007\/s12325-024-03003-8","article-title":"Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: A Systematic Review and Network Meta-analysis","volume":"41","author":"Dignass","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)3,8diazabicyclo[3.2.1]octan-8-yl) methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1016\/j.cgh.2022.12.029","article-title":"Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study","volume":"21","author":"Sandborn","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/toxsci\/kfac002","article-title":"B Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species","volume":"186","author":"Hardwick","year":"2022","journal-title":"Toxicol. Sci."},{"key":"ref_95","unstructured":"(2024, November 01). Available online: https:\/\/www.clinicaltrialsarena.com\/news\/theravance-izencitinib-ulcerative-colitis\/."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:40:13Z","timestamp":1760114413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":95,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237186"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237186","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}